Healing & Recovery Peptides

Regenerative peptides operate through multiple complementary pathways. BPC-157 promotes angiogenesis via VEGFR2 upregulation and activates the nitric oxide system through the Src kinase-caveolin-1 pathway. TB-500 (thymosin beta-4) acts through actin sequestration to promote cell migration and differentiation. Together, these mechanisms support wound healing, tendon/ligament repair, and mucosal regeneration. The inflammatory cascade is modulated through NF-kB inhibition, M1-to-M2 macrophage polarization, and cytokine regulation.

BPC-157 — a 15-amino acid synthetic peptide derived from human gastric juice with extensive preclinical evidence across tendon, ligament, muscle, bone, nerve, and GI healing. TB-500 (Thymosin Beta-4) — a 43-amino acid peptide that promotes systemic tissue repair through actin regulation and cell migration. TB4-FRAG (TB-500 Fragment 17-23) — the active fragment of thymosin beta-4, smaller and potentially more targeted. The BPC-157 + TB-500 combination (the "Wolverine Stack") is the most popular healing protocol in the peptide community, combining localized repair with systemic anti-inflammatory effects.

Named for its regenerative properties, the Wolverine Stack combines BPC-157 (250-500mcg daily, subcutaneous near injury site) with TB-500 (2-4mg loading dose twice weekly, then 1-2mg maintenance). The rationale is complementary mechanisms: BPC-157 for localized angiogenesis and tissue-specific repair, TB-500 for systemic cell migration and inflammation reduction. Typical protocols run 8-12 weeks. Initial improvements in pain and inflammation are commonly reported within 1-2 weeks, with significant tissue repair at 4-6 weeks.

BPC-157 has hundreds of preclinical studies but only three small human pilot studies (knee pain n=16, interstitial cystitis n=12, IV safety n=2). It was removed from FDA Category 2 in April 2026 and is under PCAC review for compounding eligibility. TB-500 has wound healing data from animal models. Both are WADA-prohibited substances. The theoretical concern of pathologic angiogenesis (potentially supporting tumor growth) means these peptides are contraindicated in individuals with active cancer or cancer history.